Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant.

Yamasaki M, Kimura R, Mayahara S, Maeda Y, Takahashi M, Nishida T, Oda K, Murakami T

DOI: 10.3892/mco.2019.1849
Published: 2019 Jul
Container: Molecular and clinical oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3892/mco.2019.1849,
  title = {Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant.},
  author = {Yamasaki M and Kimura R and Mayahara S and Maeda Y and Takahashi M and Nishida T and Oda K and Murakami T},
  year = {2019},
  journal = {Molecular and clinical oncology},
  doi = {10.3892/mco.2019.1849},
  url = {https://doi.org/10.3892/mco.2019.1849}
}

RIS

TY  - JOUR
TI  - Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant.
AU  - Yamasaki M
AU  - Kimura R
AU  - Mayahara S
AU  - Maeda Y
AU  - Takahashi M
AU  - Nishida T
AU  - Oda K
AU  - Murakami T
PY  - 2019
JO  - Molecular and clinical oncology
DO  - 10.3892/mco.2019.1849
UR  - https://doi.org/10.3892/mco.2019.1849
ER  -

APA

M, Y., R, K., S, M., Y, M., M, T., T, N., K, O., & T, M. (2019). Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant.. Molecular and clinical oncology. https://doi.org/10.3892/mco.2019.1849

Source records

pubmed · retrieved 2026-09-26T08:29:11.960Z